ChemGenex To Present At Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A.
May 02, 2005
ChemGenex Pharmaceuticals (ASX: CXS) today announced that Managing Director and Chief Executive Officer Greg Collier PhD, will be presenting at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference in Paris, France at 8:20 a.m. local time on May 4, 2005.
Dr. Collier will provide an overview of how the company conducts gene-based drug discovery and development and an update on the company's Phase II clinical programs, CeflatoninŽ (HHT) for the treatment of leukemias and QuinamedŽ (amonafide dihydrochloride) for the treatment of solid tumors.
Information about the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference can be found at http://www.rodmanandrenshaw.com.
About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
ChemGenex Pharmaceuticals is a gene-based pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex Pharmaceuticals currently has two compounds in Phase II clinical trial. CeflatoninŽ is in trial at the M.D. Anderson Cancer Center in Houston, Texas for both chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). QuinamedŽ is in trial at Tennessee Oncology and the Sarah Cannon Cancer Center in Nashville Tennessee for prostate cancer. The company has a significant portfolio of anti-cancer compounds, diabetes and obesity targets and depression and anxiety targets, and ongoing partnerships with Merck KGaA and Vernalis plc. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS", and is pursuing a joint listing on NASDAQ by mid 2005.
Contacts
| Dr. Greg Collier (CEO and Managing Director) |
Australia +61 3 5227 2752
USA +1 650 474 9800 ext 103 |
| Dr. Dennis Brown (President and Director) |
USA +1 650 474 9800 ext 108
Australia +61 3 5227 2703 |
Safe Harbor Statement
Certain statements made herein that use the words "estimate," 'project," "intend," "expect," "believe," and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development , the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.
